成都华神科技集团股份有限公司 2025 年第三季度报告 证券代码：000790 证券简称：华神科技 公告编号：2025-042 成都华神科技集团股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度财务会计报告是否经过审计 □是 否 1 成都华神科技集团股份有限公司 2025 年第三季度报告 （一） 主要会计数据和财务指标 一、主要财务数据 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 期增减 | 年同期增减 | | | 营业收入（元） | 165,700,815.85 | ...

Core Viewpoint - The company has experienced fluctuations in performance due to price reductions following centralized procurement of core products, adjustments in procurement strategies by downstream customers during the transition period, and the company's proactive contraction of its steel structure business [1] Group 1: Performance Impact - The company's performance in the previous year and this year has been affected by the price adjustments of core products after winning centralized procurement bids [1] - Downstream customers have altered their procurement strategies during the transition period, contributing to the performance volatility [1] - The company has actively reduced its steel structure business, which has also impacted overall performance [1] Group 2: Product and Strategy - The main raw material for the company's core product, Sanqi Tongshu Capsules, is Sanqi Saponins, which is not sold directly to the market [1] - The company plans to further explore resources within the Sanqi industry chain and aims to provide high-quality, lifestyle-oriented Sanqi health products to the public [1]

Market Overview - The Shanghai Composite Index closed at 3821.83 points, with a decline of 0.18% [1] - The total trading volume of A-shares reached 25,184.71 billion yuan [1] Technical Analysis - A total of 171 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.60 yuan, 10-day MA at 23.25 yuan, a difference of -2.80% [1] - Xiangyu Medical: 5-day MA at 54.48 yuan, 10-day MA at 55.33 yuan, a difference of -1.54% [1] - Northern Long Dragon: 5-day MA at 122.21 yuan, 10-day MA at 123.92 yuan, a difference of -1.38% [1] Stock Performance - Key stocks with notable declines include: - Innovation Medical: down 2.97% with a turnover rate of 16.99% [1] - Xiangyu Medical: down 5.95% with a turnover rate of 2.14% [1] - Northern Long Dragon: down 2.23% with a turnover rate of 20.67% [1] - Other stocks with significant declines include: - Aorui: down 5.25% [1] - Changbai Mountain: down 7.15% [1] - Hengbao Shares: down 6.73% [1]

Market Overview - The Shanghai Composite Index closed at 3781.61 points, with a decline of 1.23% [1] - The total trading volume of A-shares reached 1713.539 billion yuan [1] Technical Analysis - A total of 228 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.55 yuan, 10-day MA at 23.23 yuan, a difference of -2.92% [1] - North Long Dragon: 5-day MA at 121.67 yuan, 10-day MA at 123.65 yuan, a difference of -1.60% [1] - Xiangyu Medical: 5-day MA at 54.49 yuan, 10-day MA at 55.34 yuan, a difference of -1.53% [1] Individual Stock Performance - Significant declines in stock prices include: - Innovation Medical: down 4.27% with a turnover rate of 14.36% [1] - North Long Dragon: down 4.52% with a turnover rate of 13.85% [1] - Xiangyu Medical: down 5.86% with a turnover rate of 1.42% [1] - Other notable declines: - Shandong Mining Machine: down 4.43% [1] - Huakang Clean: down 6.50% [1] - Beautiful Ecology: down 5.15% [1] Additional Stock Data - The following stocks also showed significant declines: - Yuyin Co.: down 5.46% [2] - Kexin Information: down 5.22% [1] - Visual China: down 3.88% [1] - Stocks with notable trading activity include: - Hengbao: down 6.64% with a turnover rate of 10.88% [2] - Changbai Mountain: down 6.53% with a turnover rate of 4.05% [2]

证券日报网讯华神科技（000790）9月22日在互动平台回答投资者提问时表示，目前山东凌凯项目仍在 一期项目建设中，一期项目投资尚未全部完成。上海凌凯持有的山东凌凯股权公司暂无收购计划，后续 若有上述计划，公司将根据该事项的进展情况依据相关法律法规的规定和要求履行相应的程序并披露， 敬请关注公司公告。 ...

Group 1 - The company is currently focused on the first phase of the Shandong Lingkai project, which is still under construction and has not yet completed all investments for this phase [2] - There are no current plans for the company to acquire shares held by Shanghai Lingkai Technology in the Shandong Lingkai project [2] - The company will disclose any future plans regarding acquisitions based on the progress of the matter and in accordance with relevant laws and regulations [2]

Group 1 - The company, Huasheng Technology, announced that as of now, it and its controlling subsidiaries do not provide guarantees to entities outside the consolidated financial statements [2] - There are no overdue debts corresponding to guarantees, nor are there any guarantees related to litigation or losses due to adverse judgments [2]

证券代码：000790 证券简称：华神科技 公告编号：2025-041 成都华神科技集团股份有限公司 上述授信和担保额度在公司 2025 年度授信和担保额度预计范围内，该事项无需提交公 司董事会或股东大会审议。 三、被担保人基本情况 （一）公司名称：成都华神科技集团股份有限公司 1、注册地址：成都高新区（西区）蜀新大道1168号2栋1楼101号 2、设立时间：1988年1月27日 3、注册资本：623,719,364元人民币 关于提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 成都华神科技集团股份有限公司（以下简称"公司"或"华神科技"）于 2025 年 4 月 27 日、2025 年 5 月 22 日分别召开了第十三届董事会第二十次会议、2024 年年度股东大会， 审议通过了《关于 2025 年度公司及子公司向金融机构申请综合授信及担保额度预计的议 案》，同意 2025 年度公司（含子公司）拟申请银行及非银行金融机构综合授信 10.60 亿元 人民币，2025 年度预计新增公司及子公司相互提供担保额度（包括公司为子公司提 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1、成都华神科技集团股份有限公司（以下简称"公司"）通过西南联合产权交易所以公开挂牌方式转让 公司控股子公司西藏康域药业有限公司（以下简称"西藏康域"）51%股权（以下简称"本次交易"）。经 西南联合产权交易所审核及公司确认，确定李正洪为合格受让方，转让价格为4,250万元。 2、本次交易不构成关联交易，不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 3、交易完成后，公司将不再持有西藏康域股权，西藏康域不再纳入公司合并报表范围。 一、交易概述 为了进一步集中资源聚焦优势业务，提升公司盈利能力和核心竞争力，推动公司高质量发展，公司于 2025年8月1日召开了第十三届董事会第二十三次会议、2025年8月19日召开了2025年第一次临时股东大 会，审议通过了《关于公司拟公开挂牌转让西藏康域51%股权的议案》，同意公司公开挂牌转让控股子 公司西藏康域51%股权，并以评估值6,378.06万元作为首次挂牌底价。具体内容详见公司于2025年8月2 ...

Group 1: Product Development and Market Focus - LiFSI is used as an additive in lithium-ion battery electrolytes, enhancing conductivity and thermal stability; currently in technical modification and customer trial phases [2] - The company is focusing on the core business of the Sanqi industry chain and ecosystem, considering both internal investment and external mergers and acquisitions to enhance resource integration [3] - The Shandong Lingkai project is in the technical modification and customer trial stage, with no revenue generated yet [4] Group 2: Financial Performance and Strategic Adjustments - The company has experienced significant performance declines and losses due to price reductions after core product bidding, adjustments in customer procurement strategies, and a strategic contraction of the steel structure business [4] - The company is actively divesting non-core business investments, including transferring subsidiaries and shares in Shanghai Lingkai and Tibet Kangyu [4] - The company is evaluating potential acquisitions, such as Sichuan Meifeng, which has a strong balance sheet and a low debt ratio of around 20% [3] Group 3: Innovation and Product Diversification - The company is committed to enhancing the stability and safety of drug efficacy, with successful clinical trials for Sanqi Tongshu capsules in treating ischemic stroke [4] - The company aims to strengthen its market position in the bottled water sector, holding the top market share in Chengdu and second in Sichuan [4] - The company is exploring new product development and strategic partnerships to diversify its product offerings [4] Group 4: Investor Relations and Future Outlook - The company assures that it is not at risk of delisting and is operating normally [4] - The management emphasizes that recent divestitures were strategic decisions aimed at consolidating resources to enhance core competitiveness and long-term profitability [4] - The company is continuously monitoring market opportunities and will make investment decisions based on strategic alignment and risk assessment [3]